CSL Limited (ASX: CSL)
Australia
· Delayed Price · Currency is AUD
280.00
-6.95 (-2.42%)
May 17, 2024, 4:10 PM AEST
CSL Limited Company Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.
The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.
The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
CSL Limited
Country | Australia |
Founded | 1916 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 32,065 |
CEO | Dr. Paul F. McKenzie Ph.D. |
Contact Details
Address: 655 Elizabeth Street Melbourne, VIC 3000 Australia | |
Phone | 61 3 9389 1911 |
Website | csl.com.au |
Stock Details
Ticker Symbol | CSL |
Exchange | ASX |
Fiscal Year | July - June |
Reporting Currency | AUD |
ISIN Number | AU000000CSL8 |
Key Executives
Name | Position |
---|---|
Dr. Paul F. McKenzie Ph.D. | MD, Chief Executive Officer and Executive Director |
Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer |
Mark Dehring | Head of Investor Relations |
Gregory Boss B.S., BS(Hons), J.D. | Executive Vice President of Legal and General Counsel |
Christina Hickie | Senior Manager of Communications |
Roanne Parry | Chief Human Resources Officer |
Dr. Karen Etchberger | Executive Vice President of Quality and Business Services |
Jemimah Brennan | Head of Communications - Asia Pacific |
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. | Senior Vice President of Research |
Dr. William Mezzanotte M.D., M.P.H. | Executive Vice President and Head of Research and Development |